Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway

Fig. 6

A Fluorescent images of AO-stained SKOV3 and SKOV3TR cells treated with various therapeutic nanocomposites for 24 h. Scale bar = 50 μm. B Fluorescent images of Rhodamine 123-stained SKOV3 and SKOV3TR cells treated for 24 h with various therapeutic nanocomposites, and C corresponding quantitative analysis. Scale bar = 500 μm. D Flow cytometry analysis of intracellular ROS levels of SKOV3 and SKOV3TR cells treated for 24 h with various therapeutic nanocomposites (E) and corresponding quantitative analysis. F Western blotting of mTOR-related proteins in SKOV3 and SKOV3TR cells after treatment for 24 h with various therapeutic nanocomposites and G corresponding quantitative analysis: A, control; B, HA-miR let-7a-pGNR @MSN; C, HA-PTX-pGNR@MSN; D, PTX/miR let-7a-pGNR@MSN; E, HA-PTX/miR let-7a-pGNR@MSN. AO, acridine orange; ROS, reactive oxygen species; mTOR, mammalian target of rapamycin; HA, hyaluronic acid; let-7a, lethal-7a; pGNR, polyethylene glycol-modified gold nanorod; MSN, mesoporous silica nanoparticle; PTX, paclitaxel

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us